AstraZeneca has sold rights to experimental respiratory drug AZD7986 to US biotech Insmed in a deal valued at around $150 million.
News
Healx bags £1.5m for drug repurposing
Healx has bagged an investment of £1.5 millions to help progress its work in the field of ‘repurposing’ existing medicines for new rare diseases.
Teva divests UK, Ireland assets
Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million.
RCGP issues general practice funding warning
General practice is at risk of losing £33 million this financial year because of an underspend by Clinical Commissioning Groups (CCGs), and potentially up to £760 million in 2020 because of being left out of regional NHS plans, according to Royal College of General Practitioners.
NICE backs efficacy of Truvada for HIV PrEP
The National Institute for Health and Care Excellence has published an evidence summary on the use of Gilead’s Truvada for HIV pre-exposure prophylaxis (PrEP) in adults at high risk of infection.
PharmaTimes offers fantastic opportunity for cross-functional marketing teams
Cross-functional pharma marketing teams can still compete in the Marketer of the Year Finals on 19 October at Quintiles, Reading.
Hunt promises 25% hike in medical school places
Health secretary Jeremy Hunt is pledging 1,500 additional medical school training places in the UK every year in a bid to plug the workforce shortfall as well as reduce reliance on overseas staff.
Bayer bags EU nod for 5yr contraceptive
Bayer has been given a green light in the EU for its low-dose levonorgestrel-releasing intrauterine system as a means to prevent pregnancy.
NICE rejects MSD’s Keytruda for lung cancer
Patients with lung cancer are to be barred from routine NHS access to MSD’s immunotherapy Keytruda in England and Wales after cost regulators concluded that it could not be considered a cost-effective use of resources.
Most CCG cancer services need improving, says NHS England
The majority of clinical commissioning groups in England need to improve their cancer services to meet ambitious targets laid out by the Cancer Taskforce that are expected to save an extra 30,000 lives a year by 2020.
Syncona, CRT create new company Achilles
Syncona and Cancer Research Technology have announced the launch of a new private company – Achilles Therapeutics – that will bring together research from University College London and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research.
MundiPharma, Orexo file Zubsolv in Europe
UK-based MundiPharma and Swedish group Orexo’s have filed opioid dependence drug Zubsolv in Europe.
EU regulators to review Herceptin biosimilar
European regulators have agreed to review Samsung Bioepis’ application to market SB3, a biosimilar of Roche’s cancer drug Herceptin.
AZ’ Brilinta disappoints in arterial disease trial
AstraZeneca’s Brilinta has been hit with another setback after failing to show superiority over veteran bloodthinner clopidogrel in patients with peripheral arterial disease (PAD).
NICE puts forward Tagrisso for Cancer Drugs Fund
AstraZeneca’s Tagrisso has become the first medicine to be put forward by the National Institute for Health and Care Excellence for the new Cancer Drugs Fund as more data is collected on its effectiveness.
